From bench to bedside

Attempt to evaluate repositioning of drugs in the treatment of metastatic small cell lung cancer (SCLC)

Zoltan Lohinai, P. Döme, Zsuzsa Szilagyi, G. Ostoros, Judit Moldvay, B. Hegedűs, B. Döme, Glen J. Weiss

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Backgrounds: Based on in vitro data and results of a recent drug repositioning study, some medications approved by the FDA for the treatment of various non-malignant disorders were demonstrated to have anti-SCLC activity in preclinical models. The aim of our study is to confirm whether use of these medications is associated with survival benefit. Methods: Consecutive patients with pathologically confirmed, stage 4 SCLC were analyzed in this retrospective study. Patients that were prescribed statins, aspirin, clomipramine (tricyclic antidepressant; TCA), selective serotonin reuptake inhibitors (SSRIs), doxazosin or prazosin (α1-adrenergic receptor antagonists; ADRA1) were identified. Results: There were a total of 876 patients. Aspirin, statins, SSRIs, ADRA1, and TCA were administered in 138, 72, 20, 28, and 5 cases, respectively. A statistically significant increase in median OS was observed only in statin-treated patients when compared to those not receiving any of the aforementioned medications (OS, 8.4 vs. 6.1 months, respectively; p = 0.002). The administration of SSRIs, aspirin, and ADRA1 did not result in a statistically significant OS benefit (median OS, 8.5, 6.8, and 6.0 months, respectively). The multivariate Cox model showed that, besides age and ECOG PS, radiotherapy was an independent survival predictor (Hazard Ratio, 2.151; 95% confidence interval, 1.828-2.525; p

Original languageEnglish
Article numbere0144797
JournalPLoS One
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 6 2016

Fingerprint

Drug Repositioning
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Small Cell Lung Carcinoma
Serotonin Uptake Inhibitors
lung neoplasms
Aspirin
drug therapy
aspirin
Cells
serotonin
Pharmaceutical Preparations
Doxazosin
Clomipramine
Adrenergic Antagonists
Tricyclic Antidepressive Agents
Prazosin
Radiotherapy
cells
antidepressants
Survival

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

From bench to bedside : Attempt to evaluate repositioning of drugs in the treatment of metastatic small cell lung cancer (SCLC). / Lohinai, Zoltan; Döme, P.; Szilagyi, Zsuzsa; Ostoros, G.; Moldvay, Judit; Hegedűs, B.; Döme, B.; Weiss, Glen J.

In: PLoS One, Vol. 11, No. 1, e0144797, 06.01.2016.

Research output: Contribution to journalArticle

@article{51850513e9c84537bbd5d55ba1379d86,
title = "From bench to bedside: Attempt to evaluate repositioning of drugs in the treatment of metastatic small cell lung cancer (SCLC)",
abstract = "Backgrounds: Based on in vitro data and results of a recent drug repositioning study, some medications approved by the FDA for the treatment of various non-malignant disorders were demonstrated to have anti-SCLC activity in preclinical models. The aim of our study is to confirm whether use of these medications is associated with survival benefit. Methods: Consecutive patients with pathologically confirmed, stage 4 SCLC were analyzed in this retrospective study. Patients that were prescribed statins, aspirin, clomipramine (tricyclic antidepressant; TCA), selective serotonin reuptake inhibitors (SSRIs), doxazosin or prazosin (α1-adrenergic receptor antagonists; ADRA1) were identified. Results: There were a total of 876 patients. Aspirin, statins, SSRIs, ADRA1, and TCA were administered in 138, 72, 20, 28, and 5 cases, respectively. A statistically significant increase in median OS was observed only in statin-treated patients when compared to those not receiving any of the aforementioned medications (OS, 8.4 vs. 6.1 months, respectively; p = 0.002). The administration of SSRIs, aspirin, and ADRA1 did not result in a statistically significant OS benefit (median OS, 8.5, 6.8, and 6.0 months, respectively). The multivariate Cox model showed that, besides age and ECOG PS, radiotherapy was an independent survival predictor (Hazard Ratio, 2.151; 95{\%} confidence interval, 1.828-2.525; p",
author = "Zoltan Lohinai and P. D{\"o}me and Zsuzsa Szilagyi and G. Ostoros and Judit Moldvay and B. Hegedűs and B. D{\"o}me and Weiss, {Glen J.}",
year = "2016",
month = "1",
day = "6",
doi = "10.1371/journal.pone.0144797",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - From bench to bedside

T2 - Attempt to evaluate repositioning of drugs in the treatment of metastatic small cell lung cancer (SCLC)

AU - Lohinai, Zoltan

AU - Döme, P.

AU - Szilagyi, Zsuzsa

AU - Ostoros, G.

AU - Moldvay, Judit

AU - Hegedűs, B.

AU - Döme, B.

AU - Weiss, Glen J.

PY - 2016/1/6

Y1 - 2016/1/6

N2 - Backgrounds: Based on in vitro data and results of a recent drug repositioning study, some medications approved by the FDA for the treatment of various non-malignant disorders were demonstrated to have anti-SCLC activity in preclinical models. The aim of our study is to confirm whether use of these medications is associated with survival benefit. Methods: Consecutive patients with pathologically confirmed, stage 4 SCLC were analyzed in this retrospective study. Patients that were prescribed statins, aspirin, clomipramine (tricyclic antidepressant; TCA), selective serotonin reuptake inhibitors (SSRIs), doxazosin or prazosin (α1-adrenergic receptor antagonists; ADRA1) were identified. Results: There were a total of 876 patients. Aspirin, statins, SSRIs, ADRA1, and TCA were administered in 138, 72, 20, 28, and 5 cases, respectively. A statistically significant increase in median OS was observed only in statin-treated patients when compared to those not receiving any of the aforementioned medications (OS, 8.4 vs. 6.1 months, respectively; p = 0.002). The administration of SSRIs, aspirin, and ADRA1 did not result in a statistically significant OS benefit (median OS, 8.5, 6.8, and 6.0 months, respectively). The multivariate Cox model showed that, besides age and ECOG PS, radiotherapy was an independent survival predictor (Hazard Ratio, 2.151; 95% confidence interval, 1.828-2.525; p

AB - Backgrounds: Based on in vitro data and results of a recent drug repositioning study, some medications approved by the FDA for the treatment of various non-malignant disorders were demonstrated to have anti-SCLC activity in preclinical models. The aim of our study is to confirm whether use of these medications is associated with survival benefit. Methods: Consecutive patients with pathologically confirmed, stage 4 SCLC were analyzed in this retrospective study. Patients that were prescribed statins, aspirin, clomipramine (tricyclic antidepressant; TCA), selective serotonin reuptake inhibitors (SSRIs), doxazosin or prazosin (α1-adrenergic receptor antagonists; ADRA1) were identified. Results: There were a total of 876 patients. Aspirin, statins, SSRIs, ADRA1, and TCA were administered in 138, 72, 20, 28, and 5 cases, respectively. A statistically significant increase in median OS was observed only in statin-treated patients when compared to those not receiving any of the aforementioned medications (OS, 8.4 vs. 6.1 months, respectively; p = 0.002). The administration of SSRIs, aspirin, and ADRA1 did not result in a statistically significant OS benefit (median OS, 8.5, 6.8, and 6.0 months, respectively). The multivariate Cox model showed that, besides age and ECOG PS, radiotherapy was an independent survival predictor (Hazard Ratio, 2.151; 95% confidence interval, 1.828-2.525; p

UR - http://www.scopus.com/inward/record.url?scp=84954164846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954164846&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0144797

DO - 10.1371/journal.pone.0144797

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0144797

ER -